Browse the public certificate library of a US research-peptide wholesaler and you may find a catalog organized around codes. The index lists GLP-1S at three strengths, GLP-2T at four, and GLP-3R at four more. Nowhere on the index does the site say what molecule any code stands for. Open one GLP-2T lot record and the composition line reads tirzepatide.
That gap is the subject of this guide.
Research-grade tirzepatide procurement means buying material for in vitro laboratory work, not medicine. This guide serves US wholesale and institutional buyers who need to confirm what they are actually being quoted. A listing's product name is a claim. Only the lot record states what the material actually is. Every product discussed here is Research Use Only and is not for human or veterinary use.
Tirzepatide Wholesale Coded Names Lot Verification Cover
Coded names are common, and that is the problem worth solving
Across three US wholesale suppliers reviewed in October 2026, every one listed this compound class under codes rather than compound names. The labels observed included GLP-2T, GLP-3R, GLP-1S, GLP2-TZ and GLP3-RT, sometimes paired with a brand-style name. Buyers also encounter TRZ and Tirz in quotes and invoices.
None of those codes is governed by a registry. No body assigns them, publishes a key, or stops two suppliers from using the same string for different materials.
A code is not evidence of anything, in either direction
Being clear about this point matters a great deal. A coded label is not proof that a supplier is hiding something, and plenty of ordinary catalog reasons exist for internal SKU naming. Nor does a familiar compound name prove identity. Both are text on a page.
Your exposure as a buyer is narrower and more practical than motive. You may end up holding three documents that share no common identifier. The purchase order names a code, the invoice names something else, and the certificate names a molecule.
When those three do not connect, you cannot show which material your records describe.
What a product name actually establishes
Very little, and knowing exactly how little is useful.
Four identifiers that look like evidence but are not
A product label, a coded SKU, a CAS Registry Number and a molecular formula all describe an intended identity. They say what the supplier means to sell you. None of them measures what sits in the vial you receive.
This holds for the plain name too. A listing reading "Tirzepatide 10mg" is the same kind of claim as one reading "GLP-2T 10mg." The first is easier to read. Neither one has been tested on your material.
Two questions this guide keeps apart
Throughout, two separate questions stay separate.
First, which molecule does the supplier intend to sell? That is answered by names, codes and registry numbers, and it is usually easy.
Second, what is the material in this specific lot? That is answered by analytical records tied to a lot identifier, and it is where procurement effort belongs.
Confusing the two is the error that coded names expose. The code simply makes visible a gap that exists whatever the label says.
The reconciliation path from label to lot record
Here is the practical core of this guide. Five links in a chain, each one checkable, running from the listing you clicked to the molecule a document names.
The five steps
Step 1. The product label or code. Record exactly what the listing says, including the strength and any brand-style name. Copy the string verbatim rather than translating it in your head.
Step 2. The catalog identifier and strength. Confirm the supplier uses that same string in its own catalog, and note the strength. Codes often differ by strength, so GLP-2T 10mg and GLP-2T 30mg may carry separate documentation histories.
Step 3. The lot number being quoted. Ask which lot will ship against your order. A supplier quoting from stock can answer this. One that cannot name a lot cannot give you a lot record.
Step 4. The certificate issued for that lot. Request the document carrying that lot identifier. Not a sample certificate, not a representative one, the document for your material.
Step 5. The composition or identity line. Read the line on that certificate naming the molecule and strength. This is the first point in the chain where anything connects a code to a compound.
What this looks like on a real page
The example at the top of this guide follows the chain exactly. A public certificate index headed GLP-2T 10mg lists five lot entries. Each carries a lot identifier, an analysis date, a test type, and a composition line reading tirzepatide at the stated strength. The page title says GLP-2T throughout and never explains the code.
So the molecule is named, but only inside the record. A buyer who stops at the catalog page never sees it.
What breaks the chain
Four failures come up often, and each one is worth catching before payment.
A certificate with no lot number cannot be matched to anything. When the lot number is missing from your quote or invoice, the record sits unconnected to your order. Should the code appear nowhere on the document, you are trusting a verbal mapping. Finally, a composition line naming a different strength means the record belongs to other material.
One limitation deserves your attention here. A composition line is the issuing party's statement about what was tested. It carries whatever authority that party and that method have, and no more.
Checking a code against what you are quoted
Six questions, and the record that answers each. Use this before accepting a quotation rather than after delivery.
| What to ask the supplier | The record that answers it | What stays open if you don't get it |
|---|---|---|
| What molecule does this code designate? | The composition or identity line on a lot certificate | You are buying a string, not a known compound |
| Which lot will ship against this order? | A lot number stated on the quote or order confirmation | No document can be matched to your material |
| Which tests did that lot receive? | The test type named on each certificate for that lot | You may assume coverage the record never claims |
| Who issued the certificate? | The issuing party named on the document | You cannot tell internal testing from independent |
| Does the strength on the record match the order? | Strength stated on both the certificate and the quote | The record may belong to a different presentation |
| Is the code used consistently across documents? | Quote, invoice, label and certificate side by side | Your own records will not reconcile at audit |
Why consistency across documents matters more than it sounds
Nothing prevents two suppliers from applying the same code to different compounds, because no registry governs these strings. One supplier can also change a code between order cycles.
If your internal records show a code and your certificates show a molecule, somebody later has to reconstruct the mapping. Asking for the compound name on the quotation itself removes that work.
Why a 39-residue chain raises the stakes on identity
Tirzepatide is a 39-amino-acid modified peptide built on the GIP sequence, according to FDA labeling for the approved pharmaceutical product. Its empirical formula is C225H348N48O68 and FDA states its molecular weight as 4813.53 Da. It carries two non-coded aminoisobutyric acid residues at positions 2 and 13, plus a C-terminal amide. A lysine at position 20 is attached to 1,20-eicosanedioic acid through a linker.
Those figures describe the molecule itself, nothing more. They say nothing about any supplier's lot, and that distinction is the point of this section.
Length changes the impurity picture
Longer peptide chains require more synthesis steps, and every step is an opportunity for a coupling to fail. Some of the resulting related substances sit close to the target in both mass and chromatographic behavior.
Which means the analytical method matters a great deal. A test that separates a short peptide cleanly from its byproducts may not resolve a 39-residue chain from a close relative.
Our guide to retatrutide, tirzepatide and semaglutide covers why 39-amino-acid peptides demand LC-MS confirmation in analytical detail. Deletion sequences and their effect on an intact mass reading are explained there, so we do not repeat them here.
What this means at the purchase-order level
Identity confirmation becomes a separate line item on a long chain. It is not something a purity percentage delivers as a bonus.
So when you ask which tests a lot received, listen for whether identity was established at all. Then ask by what method, and on which material.
What the certificate still does not tell you
Reaching a lot record that names tirzepatide is progress. It is not the end of the evaluation.
Identity confirmed is not quantity confirmed
A document can establish that the material is the intended molecule and still leave the amount open. Chromatographic purity is usually reported as a percentage of detected area. Peptide content is a different measurement, because a vial may contain counter-ion and residual water that are not impurities and not peptide either.
Material reported at 99% purity can hold less peptide than the label strength suggests. Ask which figure the certificate reports, and on what basis.
One lot says nothing about the next
Review a set of lot records for a single coded SKU and the limits become visible quickly. In the public example referenced earlier, five records for one product covered different things. Three of them reported purity only, and one reported endotoxin only. One covered both, and none reported peptide content or a separate identity test.
Five documents, one product, and no consistent attribute running through them. You cannot build a trend from that, and neither can the supplier.
No public dataset reviewed for this guide establishes batch-to-batch consistency for any supplier in this market. Treat any consistency claim as something requiring evidence you have actually seen.
What a reference trace is, and what it is not
Supplier research pages often display a chromatogram described as a reference or representative profile. Some state this plainly in a footnote. Such a trace shows what the compound should look like under stated conditions.
It is not a result from your lot. Four features tell you which one you are reading. Look for a lot identifier, an analysis date, the material tested, and an identified issuing party. Where all four are missing, the trace is illustrative.
Our guide to reading a certificate of analysis for peptides covers general document anatomy. The broader vetting frame sits in our guide to verifying a peptide supplier before ordering.
SEMAGLUTIDE 5mg 2
What to confirm before you accept a wholesale quote
Documentation is a commercial term like any other. Treating it as one changes how you compare offers.
Six things to pin down in writing
Six items belong on the quotation itself rather than in a verbal assurance.
- The compound name, not only the code
- The lot number of the material being quoted
- Which tests that lot actually received
- The basis used for any content figure
- Whether the lot record is included or costs extra
- The minimum order, in the supplier's own unit
That last item causes more confusion than it should.
Minimums are quoted in different units by different suppliers
Across the suppliers reviewed, minimums appeared as vials, as kits, and as packs of a single SKU. Volume pricing attached at different thresholds in each system. One supplier applies tiers per SKU rather than per order, which changes the arithmetic on a mixed basket entirely.
Comparing a vial minimum against a kit minimum without converting is how buyers end up surprised.
Whether you receive a lot record at all varies
On one reviewed supplier the batch certificate ships with every order. Elsewhere it becomes available only at a volume tier, or can be added to a smaller order as a paid extra.
Two quotes at a similar unit price are not comparable when one includes documentation and the other does not. Put the documentation question into the comparison before you decide.
How 99 Purity Wholesale publishes its terms
Our catalog lists this compound under its compound name rather than a code, on both the tirzepatide and tirzepatide spray product pages. The published minimum order is 10 units, which is one kit, per specification. Tiered pricing runs from Starter through Tier 3, based on kit volume.
Batch-matched certificate documentation is offered on request through the button on each product page or through our certificates of analysis page. Current pricing comes through the quotation route rather than the website, and our wholesale pricing tiers guide explains how tier structures work generally.
Account access runs through a wholesale application requiring a US business, a research-use attestation, and a licensed clinic, pharmacy, distributor or research institution. To be accurate about what that is, the application is an attestation and review process, not third-party verification of the applicant.
Where regulatory status sits in all this
Tirzepatide is approved by FDA as the pharmaceutical products Mounjaro and Zepbound. That approval attaches to those specific drug products from their manufacturer.
Approval does not travel to research material
Material sold for research use is a separate regulatory object, whatever name or code appears on the label. A code neither adds regulatory status nor removes it.
Clinical trial results for the approved products establish nothing about the identity, purity, content, stability or consistency of any supplier's research-grade lot. The two bodies of evidence answer different questions and should never be collapsed.
The compounding proposal is still a proposal
FDA announced on April 30, 2026 that it proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list. The agency stated it would consider submitted comments before making a final determination. As of October 16, 2026, no final determination had been located.
Proposed is not final. Our guide to the 503B bulks list and the 2026 GLP-1 proposal covers the detail. The wider regulatory picture sits in our 2026 peptide sourcing and RUO compliance guide.
Legality has no single answer
Whether a given online purchase is lawful depends on the product, the intended use, the buyer's standing, and the law applying to that transaction. Anyone telling you the category is simply legal or simply illegal has skipped the parts that decide it.
Where your situation is unclear, that is a question for counsel rather than a supplier.
Bringing it back to the purchase order
Four words carry the whole of this guide. They are name, record, lot and result.
The name or code tells you what is intended. Your lot number connects a document to your material. Inside the record sits the molecule's name and the list of tests performed. Results tell you what those tests established, and by omission, what they did not.
Coded product names make that chain visible because they break the comfortable assumption that a familiar label is evidence. The chain was always there, whatever the label said.
If you are evaluating a tirzepatide wholesale quote, start by reviewing the product documentation for the material you are considering. Then request the lot record through the published quotation route. All material referenced here is supplied strictly for laboratory research and is not approved or intended for human use.
Sources
- FDA Mounjaro prescribing information — 39-residue count, empirical formula, molecular weight 4813.53 Da, Aib positions 2 and 13, C-terminal amide, Lys20 acylation
- EMA Mounjaro public assessment report — Linker composition; average and monoisotopic mass basis
- FDA announcement, proposed GLP-1 exclusions from the 503B bulks list — April 30, 2026 proposal; proposed not final status
- Coskun et al. 2018, Molecular Metabolism — LY3298176 development code; dual GIP and GLP-1 receptor agonist characterization
- FDA substance registry, UNII OYN3CCI6QE — CAS Registry Number 2023788-19-2
TIRZEPATIDE 10mg 3
Related Research Compounds
All compounds referenced are supplied strictly for in vitro laboratory research and analytical testing by qualified professionals. They are not FDA-approved and are not intended for human or veterinary consumption, clinical diagnostics, therapeutic use, or dietary supplementation.
